Episode

Ep 214 – Pneumococcal disease

Podcast
GPnotebook Podcast
Published
Jul 9, 2026
Duration seconds
862
Processing state
not_requested
Canonical source
https://gpnotebook.com/en-GB/podcasts/infectious-disease/ep-214-pneumococcal-disease
Audio
https://media.blubrry.com/gpnotebook/ins.blubrry.com/gpnotebook/GPnotebook-2026-138-Ep-214.mp3
JSON
/v1/public/podcasts/gpnotebook-podcast-252935/episodes/ep-214-pneumococcal-disease
Markdown
/podcast/gpnotebook-podcast-252935/ep-214-pneumococcal-disease.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/gpnotebook-podcast-252935/episodes/ep-214-pneumococcal-disease/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/gpnotebook-podcast-252935/ep-214-pneumococcal-disease.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode, Dr Roger Henderson explores pneumococcal disease and the major changes coming to the UK pneumococcal vaccination programme in 2026. Although often overshadowed by other infectious diseases, Streptococcus pneumoniae remains a leading cause of preventable morbidity and mortality worldwide, particularly among older adults, young children and immunocompromised patients. This episode discusses the microbiology and clinical manifestations of pneumococcal disease, reviews the immunological principles behind current vaccines and examines why the UK is transitioning towards the use of the 20-valent pneumococcal conjugate vaccine, or PCV20. It also looks at the wider public health implications of these policy changes and considers how evolving serotype epidemiology continues to shape vaccination strategy in modern clinical practice. Access episode show notes containing key references and take-home points at: https://gpnotebook.com/en-GB /podcasts/infectious-disease/ep-214-pneumococcal-disease . Did you know? With GPnotebook Pro, you can earn CPD credits by tracking the podcast episodes you listen to. Learn more .